Meng En, Hsu Yu-Chao, Chuang Yao-Chi
Department of Urology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Department of Urology, Linko Chang Gung Memorial Hospital, Taipei, Taiwan.
Low Urin Tract Symptoms. 2018 Jan;10(1):3-11. doi: 10.1111/luts.12214.
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom complex that may cause bothersome storage symptoms and pain or discomfort of the bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is based on clinical features, and the possibility of other conditions must be ruled out first. Although no definitive treatment is currently available for IC/BPS, various intravesical therapies are used for IC/BPS, including heparin, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, and botulinum onabotulinumtoxinA (BoNT-A). This review summarizes the intravesical therapy for IC/BPS and discusses recent advances in the instillation of liposomal-mediated BoNT-A and other newly developed intravesical therapies.
膀胱疼痛综合征(BPS)/间质性膀胱炎(IC)是一种慢性症状复合体,可导致令人烦恼的储尿症状以及膀胱疼痛或不适,对患者的生活质量产生不利影响。IC/BPS的病因尚不清楚,其原因可能是多因素的。IC/BPS的诊断基于临床特征,必须首先排除其他病症的可能性。尽管目前尚无针对IC/BPS的确定性治疗方法,但各种膀胱内治疗方法被用于IC/BPS,包括肝素、透明质酸、硫酸软骨素、聚硫酸戊聚糖、二甲亚砜、脂质体和肉毒杆菌毒素A(BoNT-A)。本综述总结了IC/BPS的膀胱内治疗,并讨论了脂质体介导的BoNT-A灌注及其他新开发的膀胱内治疗方法的最新进展。